S&P 500   5,174.35 (-0.48%)
DOW   38,272.64 (-0.48%)
QQQ   441.44 (-0.88%)
AAPL   175.97 (+0.53%)
MSFT   423.36 (-1.07%)
META   518.75 (-0.84%)
GOOGL   159.10 (-0.19%)
AMZN   187.98 (-0.57%)
TSLA   172.52 (-1.19%)
NVDA   898.26 (-0.87%)
AMD   163.74 (-3.96%)
NIO   4.35 (-2.47%)
BABA   72.90 (-2.61%)
T   16.35 (-0.43%)
F   12.83 (-1.61%)
MU   125.08 (-1.91%)
GE   156.50 (-0.57%)
CGC   8.21 (+0.74%)
DIS   116.37 (-0.67%)
AMC   2.74 (-2.14%)
PFE   26.21 (-0.49%)
PYPL   65.48 (-0.49%)
XOM   123.00 (+0.99%)
S&P 500   5,174.35 (-0.48%)
DOW   38,272.64 (-0.48%)
QQQ   441.44 (-0.88%)
AAPL   175.97 (+0.53%)
MSFT   423.36 (-1.07%)
META   518.75 (-0.84%)
GOOGL   159.10 (-0.19%)
AMZN   187.98 (-0.57%)
TSLA   172.52 (-1.19%)
NVDA   898.26 (-0.87%)
AMD   163.74 (-3.96%)
NIO   4.35 (-2.47%)
BABA   72.90 (-2.61%)
T   16.35 (-0.43%)
F   12.83 (-1.61%)
MU   125.08 (-1.91%)
GE   156.50 (-0.57%)
CGC   8.21 (+0.74%)
DIS   116.37 (-0.67%)
AMC   2.74 (-2.14%)
PFE   26.21 (-0.49%)
PYPL   65.48 (-0.49%)
XOM   123.00 (+0.99%)
S&P 500   5,174.35 (-0.48%)
DOW   38,272.64 (-0.48%)
QQQ   441.44 (-0.88%)
AAPL   175.97 (+0.53%)
MSFT   423.36 (-1.07%)
META   518.75 (-0.84%)
GOOGL   159.10 (-0.19%)
AMZN   187.98 (-0.57%)
TSLA   172.52 (-1.19%)
NVDA   898.26 (-0.87%)
AMD   163.74 (-3.96%)
NIO   4.35 (-2.47%)
BABA   72.90 (-2.61%)
T   16.35 (-0.43%)
F   12.83 (-1.61%)
MU   125.08 (-1.91%)
GE   156.50 (-0.57%)
CGC   8.21 (+0.74%)
DIS   116.37 (-0.67%)
AMC   2.74 (-2.14%)
PFE   26.21 (-0.49%)
PYPL   65.48 (-0.49%)
XOM   123.00 (+0.99%)
S&P 500   5,174.35 (-0.48%)
DOW   38,272.64 (-0.48%)
QQQ   441.44 (-0.88%)
AAPL   175.97 (+0.53%)
MSFT   423.36 (-1.07%)
META   518.75 (-0.84%)
GOOGL   159.10 (-0.19%)
AMZN   187.98 (-0.57%)
TSLA   172.52 (-1.19%)
NVDA   898.26 (-0.87%)
AMD   163.74 (-3.96%)
NIO   4.35 (-2.47%)
BABA   72.90 (-2.61%)
T   16.35 (-0.43%)
F   12.83 (-1.61%)
MU   125.08 (-1.91%)
GE   156.50 (-0.57%)
CGC   8.21 (+0.74%)
DIS   116.37 (-0.67%)
AMC   2.74 (-2.14%)
PFE   26.21 (-0.49%)
PYPL   65.48 (-0.49%)
XOM   123.00 (+0.99%)
NASDAQ:ICAD

iCAD (ICAD) Stock Price, News & Analysis

$1.70
-0.01 (-0.58%)
(As of 04/11/2024 ET)
Today's Range
$1.65
$1.75
50-Day Range
$1.35
$2.27
52-Week Range
$1.05
$3.97
Volume
70,768 shs
Average Volume
184,185 shs
Market Capitalization
$45.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

iCAD MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
164.7% Upside
$4.50 Price Target
Short Interest
Healthy
1.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.02mentions of iCAD in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.16 out of 5 stars

Computer And Technology Sector

1525th out of 1,800 stocks

Surgical & Medical Instruments Industry

244th out of 288 stocks

ICAD stock logo

About iCAD Stock (NASDAQ:ICAD)

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography. It offers PowerLook, a back-end architecture platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and PowerLook Density Assessment provides automated, consistent, and standardized breast density assessments. The company also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a clinical decision support tool that provides breast cancer risk estimation based on a screening mammogram; and VeraLook, a solution designed to support detection of colonic polyps in conjunction with Computed Tomography Colonography. In addition, it offers Xoft Axxent electronic brachytherapy systems for the treatment of early-stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

ICAD Stock Price History

ICAD Stock News Headlines

Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
ICAD Apr 2024 2.500 call
ICAD Apr 2024 2.500 put
Q4 2023 ICAD Inc Earnings Call
icad: Q4 Earnings Insights
icad earnings preview: what Wall Street is expecting
The Hot List: 3 AI Stocks Worth Buying on Weakness
See More Headlines
Receive ICAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iCAD and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/12/2024
Today
4/12/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:ICAD
Employees
108
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.50
High Stock Price Target
$5.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+164.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-4,850,000.00
Pretax Margin
-40.36%

Debt

Sales & Book Value

Annual Sales
$17.32 million
Book Value
$1.27 per share

Miscellaneous

Free Float
23,368,000
Market Cap
$45.12 million
Optionable
Optionable
Beta
1.34

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Ms. Dana R. Brown (Age 59)
    President, CEO & Executive Chair
  • Mr. Jonathan  GoMr. Jonathan Go (Age 61)
    Chief Technology Officer
    Comp: $351.89k
  • Mr. Eric Lonnqvist
    Chief Financial Officer
  • Ms. Michelle Strong
    Chief Operations Officer
  • Ms. Annette L. Heroux (Age 67)
    Vice President of Administration
    Comp: $174.9k
  • Mr. Anthony Takazawa
    Director of Investor Relations
  • Brian Testa
    Chief People Officer
  • Mr. Bill Keyes
    Senior VP of Global Sales Operations
  • Mr. Vasu Avadhanula
    Chief Product Officer
  • Mr. Peter Graham
    Senior VP of North American Sales

ICAD Stock Analysis - Frequently Asked Questions

Should I buy or sell iCAD stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iCAD in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ICAD shares.
View ICAD analyst ratings
or view top-rated stocks.

What is iCAD's stock price target for 2024?

1 analysts have issued twelve-month price targets for iCAD's stock. Their ICAD share price targets range from $4.00 to $5.00. On average, they expect the company's stock price to reach $4.50 in the next year. This suggests a possible upside of 164.7% from the stock's current price.
View analysts price targets for ICAD
or view top-rated stocks among Wall Street analysts.

How have ICAD shares performed in 2024?

iCAD's stock was trading at $1.77 at the beginning of the year. Since then, ICAD stock has decreased by 4.0% and is now trading at $1.70.
View the best growth stocks for 2024 here
.

Are investors shorting iCAD?

iCAD saw a increase in short interest in March. As of March 31st, there was short interest totaling 451,300 shares, an increase of 9.2% from the March 15th total of 413,100 shares. Based on an average daily volume of 210,300 shares, the short-interest ratio is currently 2.1 days. Currently, 1.8% of the shares of the stock are sold short.
View iCAD's Short Interest
.

When is iCAD's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ICAD earnings forecast
.

How were iCAD's earnings last quarter?

iCAD, Inc. (NASDAQ:ICAD) released its quarterly earnings results on Tuesday, March, 12th. The technology company reported ($0.02) earnings per share for the quarter. The technology company had revenue of $4.74 million for the quarter. iCAD had a negative trailing twelve-month return on equity of 21.63% and a negative net margin of 27.08%.

What is Michael Klein's approval rating as iCAD's CEO?

4 employees have rated iCAD Chief Executive Officer Michael Klein on Glassdoor.com. Michael Klein has an approval rating of 75% among the company's employees.

What other stocks do shareholders of iCAD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iCAD investors own include Inseego (INSG), Marvell Technology (MRVL), NVIDIA (NVDA), Aptiv (APTV), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Ambarella (AMBA), BioXcel Therapeutics (BTAI) and Telefonaktiebolaget LM Ericsson (publ) (ERIC).

Who are iCAD's major shareholders?

iCAD's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Salem Investment Counselors Inc. (0.28%). Insiders that own company stock include Andy Sassine, Charles Ross Carter, Dana R Brown, Jonathan Go, Michael S Klein, Stacey M Stevens, Susan Alyson Wood and Timothy Norris Irish.
View institutional ownership trends
.

How do I buy shares of iCAD?

Shares of ICAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ICAD) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners